Cardiohepatic Interactions: From Venous Congestion to Pharmacotherapy-A Narrative Review and Proposed Clinical Framework

Background: Cardiohepatic syndrome reflects bidirectional heart-liver interactions, particularly in heart failure with elevated right-sided pressures and venous congestion. Congestive hepatopathy may impair hepatic function and influence cardiovascular drug disposition. Whether congestion alters drug exposure remains uncertain. Objective: To review cardiohepatic interactions and propose a congestion-phenotyping framework. Methods: This narrative review examines venous congestion, congestive hepatopathy, liver stiffness measurement (LSM), venous excess ultrasound (VExUS), hepatic biomarkers, hemodynamics, and cardiovascular pharmacotherapy. Results: Elevated right-sided pressures and venous congestion cause hepatic hemodynamic stress and may produce congestive hepatopathy. Hepatic dysfunction can alter the disposition of cardiovascular medications. VExUS and LSM offer complementary assessments of systemic venous congestion and hepatic stiffness, but neither independently establishes fibrosis or guides drug dosing. Congestion-related changes in hepatic and renal function, protein binding, gastrointestinal absorption, and volume of distribution may affect cardiovascular drug pharmacokinetics (PK) and pharmacodynamics (PD). However, evidence linking quantified congestion to drug exposure or PD response remains limited. No prospective evidence validates VExUS- or LSM-guided dosing based on drug concentrations or established PK/PD targets. We propose a physiology-informed framework for incorporating congestion assessment into pharmacological decisions during decongestion. Conclusion: Cardiohepatic assessment should distinguish established hemodynamic effects from the unproven relationship between congestion and drug exposure. Combining clinical evaluation, biomarkers, venous ultrasound, LSM, and selected invasive hemodynamics may improve congestion phenotyping and monitoring. This framework remains hypothesis-generating, not a validated dosing strategy. Prospective studies integrating congestion measures, drug concentrations, PK/PD parameters, and outcomes are needed to determine whether congestion-informed pharmacotherapy improves safety and effectiveness.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-12
DOI
https://doi.org/10.20944/preprints202611.1285.v1
Primary Topic
Heart Failure Treatment and Management
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Cardiohepatic Interactions: From Venous Congestion to Pharmacotherapy-A Narrative Review and Proposed Clinical Framework

Dan-Cătălin Oprea, Laurențiu Șorodoc, Cristian Stătescu, Delia Lidia Șalaru et al.
Preprints.org
Heart Failure Treatment and Management
preprint

Cardiohepatic Interactions: From Venous Congestion to Pharmacotherapy-A Narrative Review and Proposed Clinical Framework

Dan-Cătălin Oprea, Laurențiu Șorodoc, Cristian Stătescu, Delia Lidia Șalaru, Iasmin Mawas, Luiza Elena Corneanu, Catalina Lionte, Radu Andy Sascău
preprint en

Abstract

Background: Cardiohepatic syndrome reflects bidirectional heart-liver interactions, particularly in heart failure with elevated right-sided pressures and venous congestion. Congestive hepatopathy may impair hepatic function and influence cardiovascular drug disposition. Whether congestion alters drug exposure remains uncertain. Objective: To review cardiohepatic interactions and propose a congestion-phenotyping framework. Methods: This narrative review examines venous congestion, congestive hepatopathy, liver stiffness measurement (LSM), venous excess ultrasound (VExUS), hepatic biomarkers, hemodynamics, and cardiovascular pharmacotherapy. Results: Elevated right-sided pressures and venous congestion cause hepatic hemodynamic stress and may produce congestive hepatopathy. Hepatic dysfunction can alter the disposition of cardiovascular medications. VExUS and LSM offer complementary assessments of systemic venous congestion and hepatic stiffness, but neither independently establishes fibrosis or guides drug dosing. Congestion-related changes in hepatic and renal function, protein binding, gastrointestinal absorption, and volume of distribution may affect cardiovascular drug pharmacokinetics (PK) and pharmacodynamics (PD). However, evidence linking quantified congestion to drug exposure or PD response remains limited. No prospective evidence validates VExUS- or LSM-guided dosing based on drug concentrations or established PK/PD targets. We propose a physiology-informed framework for incorporating congestion assessment into pharmacological decisions during decongestion. Conclusion: Cardiohepatic assessment should distinguish established hemodynamic effects from the unproven relationship between congestion and drug exposure. Combining clinical evaluation, biomarkers, venous ultrasound, LSM, and selected invasive hemodynamics may improve congestion phenotyping and monitoring. This framework remains hypothesis-generating, not a validated dosing strategy. Prospective studies integrating congestion measures, drug concentrations, PK/PD parameters, and outcomes are needed to determine whether congestion-informed pharmacotherapy improves safety and effectiveness.

Preprints.org
Good health and well-being
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon